Editas Medicine Inc (EDIT) News

Editas Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells...

Form 8-K - Current report

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing...

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE...

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

CAMBRIDGE, Mass., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage...

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage...

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Editas Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage...

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end In vivo...

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities